

Encephalitis and rapidly progressive dementia due to probable Prion disease presenting with a non-convulsive status epilepticus. Case report and literature review

Encefalitis y demencia rápidamente progresiva por probable enfermedad priónica que se presenta con un estado epiléptico no convulsivo. Reporte de caso y revisión de la literatura

Diego Alejandro Cubides-Diaz,¹ Valentina Negrette Lazaro,² Mario Rey,³ Karen Mantilla,⁴
Eder Cáceres⁵

Abstract

Prion diseases are rare and rapidly progressive fatal neurological disorders characterized by abnormal folding of neuronal proteins. The diagnosis is often challenging and relies on a high clinical suspicion, imagenological findings, electroencephalographic (EEG) patterns and cerebrospinal fluid (CSF) analysis. We present a case of probable prion disease with an accelerated neurological decline and a non-convulsive status epilepticus (NCSE), which has only been described in a few cases worldwide, and seems to be associated with worse neurological outcomes and shorter survival time. Clinical manifestations, treatment, and outcomes are shown below.

Keywords: Encephalitis, Dementia, Prion Disease, Non-convulsive status epilepticus, Creutzfeldt-Jakob syndrome

Resumen

Las prionopatías son trastornos neurológicos infrecuentes, fatales y rápidamente progresivos caracterizados por el plegamiento anormal de proteínas neuronales. Su diagnóstico es un reto frecuentemente, y se fundamenta en una alta sospecha clínica, hallazgos imagenológicos típicos, patrones electroencefalográficos sugestivos y el estudio del líquido cefalorraquídeo. Presentamos un caso de enfermedad por priones probable con un deterioro neurológico acelerado y un estado epiléptico no convulsivo, este se ha descrito en pocos casos a nivel mundial y se ha asociado con desenlaces neurológicos desfavorables y menor tasa de supervivencia. Las manifestaciones clínicas, tratamiento y desenlaces se presentan a continuación.

Palabras clave: Encefalitis, Demencia, Enfermedad por priones, Estatus epiléptico no convulsivo, Síndrome de Creutzfeldt-Jakob

Rev. Ecuat. Neurol. Vol. 33, N° 1, 2024

Introduction

Prion diseases are rapidly progressive and fatal neurological conditions of undetermined nature which can be classified into sporadic, genetic, or acquired.¹ Among the sporadic diseases, Creutzfeldt-Jakob's disease (CJD) is the most prevalent, followed by sporadic fatal insomnia and variably protease sensitive prionopathy. Genetic conditions are characterized by their dominant auto-

somal inheritance pattern, such as genetic CJD, Gerstmann-Straussler-Scheinker syndrome and fatal familial insomnia. Finally, the acquired conditions are the least prevalent and include Kuru's disease, iatrogenic CJD and variant CJD.² All of these disorders are characterized by the accumulation of abnormally folded and differentiated prion proteins called protease-resistant prion proteins (PRPSc), due to their post-translational conformation

¹Department of Internal Medicine, Internal medicine specialist, Universidad de La Sabana, Chía 140013, Colombia.

²Faculty of Medicine, General physician, Universidad del Rosario, Bogotá, 111321, Colombia.

³Faculty of Medicine, General physician, Universidad de La Sabana, Chía 140013, Colombia.

⁴Department of Intensive Care and Critical Medicine, Critical care specialist, Universidad de La Sabana, Chía 140013, Colombia.

⁵Department of Intensive Care and Critical Medicine, Neurocritical care specialist, Clínica Universidad de La Sabana, Chía 250008, Colombia.

Corresponding author:

Dr. Mario Rey

114th street #45-65, Bogotá, Colombia.

Phone number: +57-3174022225

E-mail: mariodrey13@gmail.com

into β -sheets which confers them resistance to protease activity, as opposed to the conformation of α -helices observed in the normal form of the cellular prion protein (PrPc).³ The PrPc is normally found in human brain cells anchored to neuronal plasma membranes via the glycoposphatidylinositol, while its anomalous form, the PrPSc, is usually found inside the cell predominantly in cytoplasmic vacuoles and secondary lysosomes.²

Although the functions of PRPc have not yet been fully elucidated, they have been described to contribute to cellular adhesion, neuroprotection, regulation of the circadian rhythm, maintenance of myelin, ionic homeostasis (especially related to copper), cell signaling, immunological functions and neuronal development.³⁻⁵ The alteration of neuronal proteostasis and the insufficient degradation of proteins lead to the accumulation of PrPSc. This promotes a state of cellular stress, proliferation of glial cells, absence of a classic inflammatory response, loss of synaptic signaling, and the induction of apoptotic pathways, cellular death and neuronal loss.⁶ Two theories attempt to explain the pathophysiological causes of neurotoxicity; the first one suggests that PrPSc aggregates corrupt the function of neuronal receptors such as the N-methyl-D-aspartate (NMDA) receptor, increasing the permeability of the cell membrane. The second one suggests a binding between PrPc and the membrane anchored PrPSc, acquiring the ability to act as a receptor of prionic toxicity favoring synaptotoxicity.²

The presentation and progression of these conditions are variable, but the prognosis is always ominous. They are usually suspected in cases of rapidly progressive dementia, rapid cognitive impairment, myoclonus, pyramidal or extrapyramidal symptoms, visual or cerebellar dysfunction, and akinetic mutism.⁷ The diagnosis is challenging and requires a high clinical suspicion and the combination of characteristic imagenological findings, electroencephalographic (EEG) patterns and cerebrospinal fluid (CSF) analysis; with most cases being confirmed post-mortem with histopathological studies.^{1,7} The present describes a case of probable prion disease with an accelerated neurological decline and presenting with a non-convulsive status epilepticus (NCSE), which to our knowledge has only been reported in less than twenty cases worldwide.⁸⁻²⁰

Case report

A 69-year-old male with history of arterial hypertension and without any family medical records, presented to the emergency department with a two-month history of headache, recurrent amnesia, bradypsychia delirium and apathy without functional impairment. His symptoms worsened in the last 20 days presenting functional dependence for basic daily activities, unsteady gait, aggressive behavior, and myoclonic jerks of the lower limbs predominantly noc-

turnal. Before admission, a magnetic resonance imaging (MRI) of the brain was performed in the ambulatory setting revealing hyperintensities in the right anterior, medial occipital and lateral frontal cortex in diffusion weighted images (DWI). On admission he was alert, disoriented, with reduced activity and slowness, limited facial expressions and with no verbal response compatible with akinetic mutism. Vital signs were normal except for mild hypertension. A computed tomography of the brain was normal, and initial laboratories revealed a mild leukocytosis with neutrophilia and elevated serum creatinine. Lumbar puncture was performed revealing an increased protein level, with normal opening pressure and leukocyte count (Table 1).

Table 1. Laboratory findings

Laboratory	Admission	Day 12
White blood cell count (103/ μ L)	12	10,99
Neutrophils (%)	72	81,5
Hemoglobin (mg/dL)	16,2	12,5
Hematocrit (%)	43,9	35,3
Platelet count (103/mL)	344	255
Creatinine (mg/dL)	1,38	1,13
Blood urea nitrogen (mg/dL)	18	37,5
Sodium (mmol/L)	141	139
Potassium (mmol/L)	3,7	3,75
Chloride (mmol/L)	103	98,6
Magnesium (mg/dL)	2,21	2,2
D-dimer (ng/mL)	450	-
Prothrombin time (seconds)	10,4	-
Partial thromboplastin time (seconds)	27,6	-
C-reactive protein (mg/L)	1,6	201
Lumbar puncture	Admission	Day 12
Opening pressure (cmH ₂ O)	9	11
Appearance	Clear	Clear
pH	7	7,1
Glucose (mg/dL)	61	119
Protein level (mg/dL)	73	37
Red blood cell count (mm ³)	1	0
White blood cell count (mm ³)	0	0
Gram stain	Negative	Negative
Indian Ink stain	Negative	Negative
Direct microscopy	Negative	Negative
Non-treponemal (VDRL) test	Non reactive	Non reactive
Microbiological culture	Negative	Negative
N-methyl-D-aspartate receptor autoantibodies	-	Negative
Adenosine deaminase (U/L)	-	0,22
Multiplex polymerase chain reaction meningitis/encephalitis panel (BioFire® FilmArray® System): <i>Escherichia coli</i> K1, <i>Haemophilus influenzae</i> , <i>Listeria monocytogenes</i> , <i>Neisseria meningitidis</i> , <i>Streptococcus agalactiae</i> , <i>Streptococcus pneumoniae</i> , Human Parechovirus (HPeV), Enterovirus (EV), Herpes simplex virus 1 (HSV-1), Herpes simplex virus 2 (HSV-2), Human Herpesvirus 6 (HHV-6), Cytomegalovirus (CMV), Varicela-zoster virus (VZV), <i>Cryptococcus neoformans/gatti</i>	-	No microorganisms reported

On day 3 of admission the patient presented neurological decline with dysphagia, recurrent myoclonic jerks at night time, and behavioral impairments such as aggression, psychomotor agitation and incomprehensible language. A new MRI of the brain revealed an increase on the hyperintense areas on DWI (figure 1) ruling out neoplastic, ischemic or bleeding processes.




Figure 1. MRI of the brain with flair (left) and diffusion (right) weighted images revealing hyperintensities on the upper left parasagittal frontoparietal cortex, right head of caudate nucleus, and on the right side of the anterolateral and upper frontal temporal occipital cortex.

A few days later, consciousness began to deteriorate and an EEG revealed a NCSE with moderate encephalopathy, delta/theta triphasic activity and a symmetric fluctuating frequency of 2.5 Hz throughout the reading (Figure 2). These findings were considered suggestive of sporadic onset prionopathy, and the patient was started on valproic acid 1000 mg initial dose, then 500 mg every 8 hours. Later it was necessary to add therapy with levetiracetam 1000 mg every 8 hours. Other causes of encephalopathy were taken into consideration, such as paraneoplastic syndrome and autoimmune encephalitis, for which a contrast tomography of the chest and abdomen were performed with normal results, and a therapeutic test of intravenous pulsed methylprednisolone 1000 mg every 24 hours for 5 days was initiated, with no neurological improvement. A new EEG was performed 8 days after the first one without significant changes compared to the initial, with persistence of delta/theta activity of triphasic morphology with a frequency of 2.5 Hz symmetrical that increases and decreases along the route, compatible with NCSE.




Figure 2. EEG tracing with triphasic delta / theta activity, with a 2-2.5 Hz frequency in the left hemisphere and a maximum negativity at C3 that increases and decreases throughout the trace. These findings are present in the 50% of the reading, and are compatible with definitive NCSE. No clinical crises were documented.

On day 7 of hospitalization the neurological condition continued to deteriorate progressively. A state of stupor and a Glasgow coma score (GCS) of 7 prompted a transfer to the intensive care unit for invasive mechanical ventilation and deep sedation. A new lumbar puncture was performed which revealed a CSF of the same characteristics as the one before, with a negative FilmArray® Meningitis/Encephalitis panel (Biomerieux) and a negative report of NMDA antibodies. It should be noted that an expanded panel of antibodies was not performed due to its unavailability. In order to evaluate the neurological condition, a sedation vacation was initiated 48 hours after ICU admission with poor neurological response, therefore a therapeutic failure of intravenous corticosteroid pulses was considered and the likelihood of autoimmune encephalitis decreased suggesting a diagnosis of prion disease. Although the diagnosis of autoimmune encephalitis could not be ruled out comple-

tely, the rapid clinical and neurological deterioration, the poor neurological prognosis and the willing of the family members to limit additional interventions; made unviable to consider other therapeutic alternatives such as plasma exchange or intravenous immunoglobulin. Scheduled extubation was performed and persistence of unsatisfactory neurological evolution promptly led to bradycardia, hypotension and asystole. Decease presented fourteen days after hospital admission, and clinical autopsy was suggested but not permitted by the family members.

Discussion

The diagnosis workup of patients presenting with rapidly progressive dementia includes ruling out metabolic, infectious, autoimmune and paraneoplastic disorders. Prion diseases are usually considered as exclusion diagnoses, especially due to the limited availability of confirmation tests and the poor prognosis, with a median survival time of 4 months from the onset of symptoms.²¹ Some additional characteristics could aid in the diagnosis of prion diseases, such as the presence of myoclonic jerks and visual or cerebellar disturbances.²¹ The most common imaging finding is the presence of hyperintensities in the head of the caudate and putamen nucleus in MRI diffusion weighted images. CSF can also be tested in these patients and usually presents with high levels of 14-3-3 protein, neuron-specific enolase and tau protein.²¹⁻²³ EEG findings are, however, very variable. The most common EEG pattern is the presence of periodic discharges initially lateralized and later becoming generalized during the course of the illness. This pattern has been described in up to 77 % of the patients, but there have also been described cases with normal EEG tracings.²¹ Recently, real-time quaking-induced conversion (RT-QuIC) has been considered as one of the most effective diagnostic techniques for prion disease. This test induces PRPc conversion into a poorly folded form which can be controlled and detected in real time by fluorescent stainings.²⁴ The gold-standard diagnostic method remains the detection of the abnormal protein in tissue samples, which can be performed by immunohistochemistry or western blot techniques.^{25,26}

The present case has many elements that suggest a probable prion disease. Amongst those are the clinical

presentation, the MRI findings and the exclusion of other conditions associated with rapidly progressive dementia such as autoimmune encephalitis, metabolic disorders, neoplastic diseases and neuroinfection. It was not possible to confirm this condition since we couldn't perform specific protein measurements in CSF or histopathological studies. However, according to the 2018 CDC's Diagnostic Criteria for Creutzfeldt-Jakob Disease, it could be classified into probable CJD given the presence of rapidly progressive dementia, myoclonus, akinetic mutism, compatible cerebral MRI findings and the ruling out of alternative diagnostics.²⁷ An interesting aspect of the case is the presence of a NCSE, which has been described only in a few cases of CJD. A scoping review of the literature describes the association of CJD and NCSE in only 14 cases to our knowledge,⁸⁻²⁰ half of these cases being classified as probable CJD as ours. The clinical presentation and outcomes of these cases are presented in Table 2.

There are currently no treatment options for this group of neurodegenerative disorders, which have a devastating clinical course with high mortality rates from the time of their first clinical manifestations.¹ Cases that presented with NCSE had a mean survival time of 2.8 months since the beginning of symptoms,⁸⁻²⁰ in comparison with cases that presented with other EEG findings that reported a mean survival time of 4 months in some series.²¹ This could suggest that the presence of a NCSE in the course of the disease correlates with a worse prognosis and shorter survival time. This association has not been described previously and warrants further investigation.

Conclusions

Overall, prion diseases are a group of rare disorders characterized by rapid clinical and neurological deterioration and a high mortality rate. There are many studies that could aid in the diagnosis of these conditions, but not all of these are universally accessible and, in some cases, only MRI of the brain and EEG tracings are available, often making prion diseases an exclusion diagnosis. The present case describes one of the few probable cases of prion disease associated with a NCSE, and reviews the possible association of NCSE with worse outcomes and a shorter survival time in patients with these disorders.

Table 2. Cases of prion disease and non convulsive status epilepticus (NCSE)

Reference	Age (years) / Sex	Symptoms at onset	EEG findings	Cerebral MRI findings (DWI)	Diagnostic classification	Time from onset to death (months)
Rees et al. 1999 (8)	58 / W	Mood disturbances, confusion, unsteady gait	Continuous variable amplitude sharp waves in all areas although with a R-sided emphasis, with a repetitive appearance up to 2 per second	HP in the parieto-occipital white matter involving the right centrum semiovale with mass effect	Definite	-
Rees et al. 1999 (8)	68 / M	Confusion, abnormal behavior, dysphasia, obtundation	Periodic lateralized epileptiform discharges more marked on the L side	-	Probable	-
Fernandez-Torre et al. 2003 (9)	75 / W	Confusion, abnormal behavior, dysphasia, trouble walking	Continuous diffuse spikes, rhythmic sharp waves, sharp-and-slow wave complexes	-	Definite	2
Cohen et al. 2004 (10)	26 / M	Confusion, progressive language difficulties, dysphasia	Rhythmic 2-4-Hz delta activity intermixed with sharp waves, with a clear amplitude predominance over the L temporal region	HP involving the head of the R caudate and lentiform nuclei, and the R insula	Definite	2,5
Shapiro et al. 2004 (11)	71 / W	Weakness, fatigue, memory loss, language difficulties	Repetitive sharp waves confined to the R frontocentral region, disorganized background with theta, delta and beta frequencies	Diffuse cortical volume loss, periventricular small vessel disease and mild restricted diffusion in the R cerebrum and L frontal lobe	Definite	2,1
Rosseti et al. 2007 (12)	74 / W	Confusion, R extrapyramidal rigidity, rapidly progressive worsen of mental status	Iso-organized alpha-theta background with intermittently superimposed irregular spikes (about 2-3 Hz) non-reactive, slightly predominating on the R region	-	Probable	1
Lowden et al. 2008 (13)	49 / W	L upper extremity weakness, L upper extremity myoclonic activity and spasticity	Periodic lateralized epileptiform discharges with nearly continuous spike wave discharges seen arising predominantly from the R region	HP involving bilateral caudates, putamens and thalami pulvinars	Definite	2,3
Aiguabella et al. 2010 (14)	44 / M	Vertigo, gait abnormalities, tremor of the upper extremities	Continuous generalized periodic epileptiform discharges with a frequency of 1.5 Hz	HP in both caudate and lentiform nucleus and different cortical areas	Definite	5
Espinosa et al. 2010 (15)	64 / W	Decline in mental status, tremor in extremities	Generalized slowing and periodic epileptiform discharges at frequency of 1-1.5Hz	HP in the R caudate and few areas of the cerebral white matter	Definite	2,1
Coric et al. 2012 (16)	57 / W	Confusion, vomiting, headache	Diffuse spike-wave complex discharges at a rate of 2-3 Hz	High signal abnormalities in the insular cortex bilaterally and in the R temporal region	Probable	6,2
Rakitin et al. 2018 (17)	74 / W	Language difficulties, trouble walking and swallowing	Pseudoperiodic lateralized epileptiform discharges over the R hemisphere with a frequency of 2-3 Hz	Small periventricular and subcortical white matter lesions compatible with ischaemic leukoencephalopathy	Definite	2
Mahboob et al. 2018 (18)	60 / M	Confusion, progressively language difficulties	Focal seizure activity from L frontal region	Cytotoxic edema in the L frontal and parietal lobe with punctate calcified lesions in the R cortex	Probable	2
Katsikaki et al. 2020 (19)	57 / M	Confusion, cognitive impairment, unsteady gait	Theta activity followed by delta activity on the L frontotemporal area	Restriction of diffusion in the frontal and parietal cortex, insula, as well as in the head of the caudate nucleus and the anterior part of the putamen on the L	Probable	4
Srichawla et al. 2022 (20)	59 / M	Intermittent myoclonic jerks, moderate cognitive impairment, ataxic gait	Occasional generalized periodic discharges more predominant in the bifrontal leads with triphasic morphology typically at 1-2.0 Hz	HP of the bilateral temporal gyri in a cortical pattern consistent with cortical ribboning	Probable	-
Cubides et al. 2023*	69 / M	Cognitive impairment, unsteady gait, aggressive behavior and myoclonic jerks	Triphasic delta / theta activity with a 2-2.5 Hz frequency in the L hemisphere, and a maximum negativity at C3 that increases and decreases throughout the trace	HP on the upper L parasagittal frontoparietal cortex, R head of caudate nucleus, and on the R side of the anterolateral and upper frontal temporal occipital cortex	Probable	3

Abbreviations: F: female, HP: hyperintensities, L: left, M: male, R: right

* Current case presented above.

References

1. Baldwin KJ, Correll CM. Prion Disease. *Semin Neurol.* 2019 Aug;39(4):428-439. <https://doi.org/10.1055/s-0039-1687841>
2. Sigurdson CJ, Bartz JC, Glatzel M. Cellular and Molecular Mechanisms of Prion Disease. *Annu Rev Pathol.* 2019 Jan 24;14:497-516. <https://doi.org/10.1146/annurev-pathmechdis-012418-013109>
3. Harris DA. Cellular biology of prion diseases. *Clin Microbiol Rev.* 1999 Jul; 12(3): 429–444. <https://doi.org/10.1128/cmr.12.3.429>
4. Toni M, Massimino ML, Griffoni C, Salvato B, Tomasi V, Spisni E. Extracellular copper ions regulate cellular prion protein (PrPC) expression and metabolism in neuronal cells. *FEBS Lett.* 2005 Jan 31;579(3):741-4. <https://doi.org/10.1016/j.febslet.2004.12.053>
5. Isaacs JD, Jackson GS, Altmann DM. The role of the cellular prion protein in the immune system. *Clin Exp Immunol.* 2006 Oct;146(1):1–8. <https://doi.org/10.1111/j.1365-2249.2006.03194.x>
6. Prusiner SB. The prion hypothesis. In: Prions, Prusiner SB, McKinley MP (Eds), Academic Press, San Diego 1987. p.17
7. Uslu FI, Gokcal E, Gursoy AE, Kolukisa M, Yildiz GB. Creutzfeldt-Jakob Disease: A single center experience and systemic analysis of cases in Turkey. *Ideggyogy Sz.* 2020 Mar 30;73(05–06):177–84. <https://doi.org/10.18071/isz.73.0177>
8. Rees JH, Smith SJ, Kullmann DM, Hirsch NP, Howard RS. Creutzfeldt-Jakob disease presenting as complex partial status epilepticus: a report of two cases. *J Neurol Neurosurg Psychiatry.* 1999;66(3):406–7. <https://doi.org/10.1136/jnnp.66.3.406>
9. Fernández-Torre JL, Solar DM, Astudillo A, Cereceda R, Acebes A, Calatayud MT. Creutzfeldt-Jakob disease and non-convulsive status epilepticus: A clinical and electroencephalographic follow-up study. 2004 Feb;115(2):316-9. <https://doi.org/10.1016/j.clinph.2003.10.012>
10. Cohen D, Kutluay E, Edwards J, Peltier A, Beydoun A. Sporadic Creutzfeldt-Jakob disease presenting with nonconvulsive status epilepticus. *Epilepsy Behav.* 2004 Oct;5(5):792–6. <https://doi.org/10.1016/j.yebeh.2004.06.019>
11. Shapiro JM, Shujaat A, Wang J, Chen X. Creutzfeldt-Jakob disease presenting as refractory non-convulsive status epilepticus. *J Intensive Care Med.* 2004 Nov-Dec;19(6):345-8. <https://doi.org/10.1177/0885066604269771>
12. Rossetti AO, Dunand M. Creutzfeldt-Jakob disease: evolution from nonconvulsive status epilepticus, through SIRPIDs, to generalized periodic discharges. *Clin Neurophysiol.* 2007 Nov;118(11):2533–6. <https://doi.org/10.1016/j.clinph.2007.08.002>
13. Lowden MR, Scott K, Kothari MJ. Familial Creutzfeldt-Jakob disease presenting as epilepsy partialis continua. *Epileptic Disord.* 2008 Dec;10(4):271–5. <https://doi.org/10.1684/epd.2008.0216>
14. Aiguabella M, Falip M, Veciana M, Bruna J, Palasí A, Corral L, et al. Refractory nonconvulsive status epilepticus in Creutzfeldt-Jakob disease. *Epileptic Disord.* 2010 Sep;12(3):239–42. <https://doi.org/10.1684/epd.2010.0318>
15. Espinosa PS, Bensalem-Owen MK, Fee DB. Sporadic Creutzfeldt-Jakob disease presenting as nonconvulsive status epilepticus case report and review of the literature. *Clin Neurol Neurosurg.* 2010 Jul;112(6):537–40. <https://doi.org/10.1016/j.clin-neuro.2010.03.025>
16. Ćorić L, Vargek-Solter V, Supanc V, Miškov S, Drnasin S, Sabolek K, et al. Sporadic Creutzfeldt-Jakob disease in a patient with episodes of nonconvulsive status epilepticus: case report. Vol. 51, *Acta Clin Croat.* 2012.
17. Rakitin A, Vibo R, Veikat V, Ōunapuu A, Liigant A, Haldre S. Creutzfeldt-Jakob Disease Presenting as Nonconvulsive Status Epilepticus. *Case Rep Neurol Med.* 2018 Nov 4;2018:1–4. <https://doi.org/10.1155/2018/3092018>
18. Mahboob HB, Kaokaf KH, Gonda JM. Creutzfeldt-Jakob Disease Presenting as Expressive Aphasia and Nonconvulsive Status Epilepticus. *Case Rep Crit Care* 2018 Feb 14; 2018:5053175. <https://doi.org/10.1155/2018/5053175>
19. Katsikaki G, Dagklis IE, Angelopoulos P, Ntanos D, Prevezianou A, Bostantjopoulou S. Atypical and early symptoms of sporadic Creutzfeldt - Jakob disease: case series and review of the literature. *Int J Neurosci* 2021 Sep;131(9):927-938. <https://doi.org/10.1080/00207454.2020.1759594>
20. Srichawla BS. Sporadic Creutzfeldt-Jakob Disease With Status Epilepticus: Molecular Mechanisms and a Scoping Review of the Literature. *Cureus.* 2022 Sep 1; 14(8). <https://doi.org/10.7759/cureus.28649>
21. Muthusamy S, Garg P, Chandra R V., Seneviratne U. How common are seizures in the heidenhain variant of creutzfeldt-jakob disease? A case report and systematic review. *J Clin Neurosci.* 2021 Apr 1;86:301–9. <https://doi.org/10.1016/j.jocn.2020.10.002>

22. Kohira I, Tsuji T, Ishizu H, Takao Y, Wake A, Abe K, et al. Elevation of neuron-specific enolase in serum and cerebrospinal fluid of early stage Creutzfeldt-Jakob disease. *Acta Neurol Scand*. 2000 Dec;102(6):385-7. <https://doi.org/10.1034/j.1600-0404.2000.102006385.x>
23. Tudorică V, Bălșeanu TA, Albu VC, Bondari S, Bumbea AM, Pîrșcoveanu M. Tau protein in neurodegenerative diseases - a review. *Rom J Morphol Embryol*. 2017;58(4):1141-1150.
24. Green AJE. RT-QuIC: a new test for sporadic CJD. *Pract Neurol*. 2019 Feb 1; 19(1):49–55. <https://doi.org/10.1136/practneurol-2018-001935>
25. Safar JG, Geschwind MD, Deering C, Didorenko S, Sattavat M, Sanchez H, et al. Diagnosis of human prion disease. *Proc Natl Acad Sci U S A*. 2005 Mar 1; 102(9):3501–6. <https://doi.org/10.1073/pnas.0409651102>
26. Appleby BS, Yobs DR. Symptomatic treatment, care, and support of CJD patients. *Handb Clin Neurol*. 2018 Jan ;153:399–408. <https://doi.org/10.1016/B978-0-444-63945-5.00021-0>
27. CDC. CJD Diagnostic Criteria, In: Classic Creutzfeldt-Jakob Disease. CDC. 2024. <https://www.cdc.gov/prions/cjd/diagnostic-criteria.html>

Funding: *This research received no external funding*

Conflicts of interest: *The authors declare no conflicts of interest.*

Institutional Review Board Statement: *The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of Universidad de La Sabana Clinic.*

Informed Consent Statement: *Written informed consent was obtained from the patient's family to publish this paper.*

Data Availability Statement: *All relevant information has been presented in the case report. Any additional data may be made available on reasonable request from the corresponding author.*